Data layers Raw facts Calculated Model prediction AI interpretation

IPO Timeline Raw facts

Broker Deadline
Morning deadline
HKEX Deadline
Noon deadline
Broker Results (T-2)
Some brokers release in afternoon
Grey Market (T-1)
Afternoon
HKEX Allotment (T-1)
Evening
Registrar Allotment (T-1)
Evening
Listing Day (T)
First day of trading

Company Overview

Stock NameSunho Bio-B
Stock Code02898
Company Full NameSunho Biologics, Inc.
Industry醫療保健
Principal Activities公司是一家生物制藥公司,致力于發現、開發和商業化生物制劑,通過直接調節先天和適應性免疫系統來調節免疫微環境,目前擁有三種核心產品,即IAH0968、IAP0971及IAE0972,均為自主研發。
Listing Date2024-05-24
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國江蘇省南京市南京經濟技術開發區興建路5號
Business Address (Hong Kong)To be extracted
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitehttp://www.sunho-bio.com.cn/
Share Registrar香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited)
Registrar Contact(852)2862 8628
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism 18A生物科技
Offer PriceHK$ 13.50 / shares
Offer Price RangeFinal offer price only, no range
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueTo be extracted
Offer PeriodTo be extracted
Global Offering Shares34,151,800 shares
HK Public Offer Shares (Initial)To be extracted
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)To be extracted
Offer RatioTo be extracted
Total Shares Post-IPOTo be extracted
Greenshoe (Over-allotment Option)No
Stabilizing Manager (Greenshoe)—
Cornerstone Share9.1%
Clawback TiersTo be extracted
Reallocation OptionNo
Total Global Offering SizeHK$ 461,049,300

Stock Connect Inclusion Analysis

26Q4 Regular Review
Inclusion Pathway Regular Path
Avg Daily HK Mkt Cap HK$ 1.01B
Est. Threshold HK$ 9.69B
Analysis Result HK market cap below threshold, need +863%

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E RatioNot disclosed
Profit/Loss StatusTo be extracted
Period-End Cash BalanceRMB 125.07 million
Listing Expenses~HK$ 69,400,000
Listing Expenses / Funds Raised~15.0%
Total Pre-IPO InvestmentRMB 311.52 million
First Day CloseHK$ 14.52
First Day OpenHK$ 14.46
First Day Change7.56%
First Day Volume2768400.0
First Day Turnover41081400.0
Use of Proceeds
1、28.2%或約110.4百萬港元將用于IAH0968在中國正在進行及計劃進行的臨床試驗; 2、35.8%或約140.1百萬港元將用于IAP0971在中國正在進行及計劃進行的臨床試驗; 3、36.0%或約141.1百萬港元將用于IAE0972在中國正在進行及計劃進行的臨床試驗。

Underwriting Syndicate

Sole Sponsor (1)
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (1)
中国国际金融香港证券有限公司 CE AEN894
Joint Bookrunners (9)
中国国际金融香港证券有限公司 CE AEN894 中国银河国际证券(香港)有限公司 CE AXM459 招银国际融资有限公司 CE AVM940 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 农银国际证券有限公司 CE ACX411 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 CITRUS SECURITIES LIMITED CE BPX754 老虎证券(香港)环球有限公司 CE BMU940 富途证券国际(香港)有限公司 CE AZT137
Joint Lead Managers (11)
中国国际金融香港证券有限公司 CE AEN894 中国银河国际证券(香港)有限公司 CE AXM459 招银国际融资有限公司 CE AVM940 ZHONGTAI INTERNATIONAL SECURITIES LIMITED CE BAA855 农银国际证券有限公司 CE ACX411 ICBC INTERNATIONAL SECURITIES LIMITED CE ARO299 CITRUS SECURITIES LIMITED CE BPX754 老虎证券(香港)环球有限公司 CE BMU940 富途证券国际(香港)有限公司 CE AZT137 VICTORY SECURITIES COMPANY LIMITED CE ABN091 China Enterprise Securities Company Limited CE ADJ832

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 南京经开未来科技产业投资合伙企业(有限合伙) 41,798,700 HKD — 9.07% — 6 months 2024-11-24

Directors & Management

PositionChinese nameEnglish Name
Chairman張峰—
Company Secretary徐春芹;黃凱婷—
No director data available.

Major Shareholders

Major Shareholders & HoldingsSunho Wisdom Investments Limited(56.17%);湖州市倚鋒安盛創業投資合伙企業(有限合伙)(7.45%)
AI AI Analysis AI interpretation deepseek-v4-pro · AI-generated
!
Underlying data failed quality checks; AI interpretation downgraded and shown for reference only.

Market Sentiment

The public offer was oversubscribed by 10.08 times, indicating moderate enthusiasm. The hit rate of 39.22% is relatively high, reflecting that the allocation was not excessively competitive. Reallocation from the international tranche suggests that institutional demand was softer, making more shares available to retail investors. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Tier Analysis

No tier distribution data was provided, making it impossible to analyze 甲尾/乙头 inefficiencies or broker fee dynamics. Investors should refer to the official allocation results for detailed tier-level statistics. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

Demographics

Demographic data for this IPO was not available in the provided dataset. Typically, Hong Kong IPO filings include breakdowns of applicant regions and identity types, but they were missing here. (This is AI-generated commentary based on historical data. Past patterns do not guarantee future outcomes. Not financial advice.)

About this page

This page shows Sunho Bio-B (02898) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect